Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Mol Biol (Mosk) ; 50(2): 347-52, 2016.
Artigo em Russo | MEDLINE | ID: mdl-27239856

RESUMO

Bacterial ribonuclease binase is a potential anticancer agent. In the present study, we have determined the toxic effect of binase towards cell lines of T-cell acute lymphoblastic leukemia Jurkat and CEMss. We have shown that binase induces apoptosis in these cells. At the same time, binase does not cause toxic effects in leukocytes of healthy donors, which suggests that binase activity towards leukemic cells is selective. We have found that the treatment of cancer cells with binase leads to a reduction in reactive oxygen species and transcription factor NFκB levels, and demonstrated that these effects are a common feature of the action of RNases on cancer cells.


Assuntos
Apoptose/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Endorribonucleases/administração & dosagem , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamento farmacológico , Bacillus/enzimologia , Humanos , Células Jurkat , NF-kappa B/metabolismo , Leucemia-Linfoma Linfoblástico de Células Precursoras/patologia , Espécies Reativas de Oxigênio/metabolismo , Linfócitos T/efeitos dos fármacos , Linfócitos T/metabolismo
2.
Cell Cycle ; 12(13): 2120-31, 2013 Jul 01.
Artigo em Inglês | MEDLINE | ID: mdl-23759588

RESUMO

Exogenous ribonucleases are known to inhibit tumor growth via apoptosis induction in tumor cells, allowing to consider them as promising anticancer drugs for clinical application. In this work the antitumor potential of binase was evaluated in vivo and the mechanism of cytotoxic effect of binase on tumor cells was comprehensively studied in vitro. We investigated tumoricidal activity of binase using three murine tumor models of Lewis lung carcinoma (LLC), lymphosarcoma RLS 40 and melanoma B-16. We show for the first time that intraperitoneal injection of binase at a dose range 0.1-5 mg/kg results in retardation of primary tumor growth up to 45% in LLC and RLS 40 and inhibits metastasis up to 50% in LLC and RLS 40 and up to 70% in B-16 melanoma. Binase does not exhibit overall toxic effect and displays a general systemic and immunomodulatory effects. Treatment of RLS 40-bearing animals with binase together with polychemotherapy revealed that binase decreases the hepatotoxicity of polychemotherapy while maintaining its antitumor effect. It was demonstrated that the cytotoxic effect of binase is realized via the induction of the intrinsic and extrinsic apoptotic pathways. Activation of intrinsic apoptotic pathway is manifested by a drop of mitochondrial potential, increase in calcium concentration and inhibition of respiratory activity. Subsequent synthesis of TNF-α in the cells under the action of binase triggers extrinsic apoptotic pathway through the binding of TNF with cell-death receptors and activation of caspase 8. Thus binase is a potential anticancer therapeutics inducing apoptosis in cancer cells.


Assuntos
Antineoplásicos/farmacologia , Apoptose , Carcinoma Pulmonar de Lewis/tratamento farmacológico , Endorribonucleases/farmacologia , Linfoma não Hodgkin/tratamento farmacológico , Melanoma Experimental/tratamento farmacológico , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/toxicidade , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Carcinoma Pulmonar de Lewis/secundário , Linhagem Celular Tumoral , Proliferação de Células , Ciclofosfamida/farmacologia , Ciclofosfamida/uso terapêutico , Citocinas/sangue , Doxorrubicina/farmacologia , Doxorrubicina/uso terapêutico , Ensaios de Seleção de Medicamentos Antitumorais , Endorribonucleases/administração & dosagem , Endorribonucleases/toxicidade , Injeções Intramusculares , Injeções Intraperitoneais , Fígado/efeitos dos fármacos , Fígado/patologia , Linfoma não Hodgkin/sangue , Melanoma Experimental/secundário , Potencial da Membrana Mitocondrial/efeitos dos fármacos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Endogâmicos CBA , Transplante de Neoplasias , Prednisona/farmacologia , Prednisona/uso terapêutico , Espécies Reativas de Oxigênio/metabolismo , Carga Tumoral/efeitos dos fármacos , Vincristina/farmacologia , Vincristina/uso terapêutico
3.
Mol Gen Mikrobiol Virusol ; (1): 25-9, 2012.
Artigo em Russo | MEDLINE | ID: mdl-22702141

RESUMO

An increase in the nitric oxide (NO) biosynthesis in Lactobacillus plantarum 8P-A3 cells takes place under strong stress influence, which leads to a considerable decrease in the microbial cell viability: heating at 70 degrees C and 80 degrees C, prolonged cultivation, toxic effect of hexylresorcinol. The factors, which do not lead to cell death, such as heating at 60 degrees C, 50 microg/ml homoserine lactone, Bacillus intermedius 7P ribonuclease (binase) in concentrations up to 300 microg/ml, do not induce NO synthesis. The activation of the NO biosynthesis in response to stress treatment evidences to universality of key-mechanisms of stress response in cells differing in the level of their organization as well as to important role of nitric oxide in them.


Assuntos
Sobrevivência Celular/efeitos dos fármacos , Lactobacillus plantarum/metabolismo , Óxido Nítrico/biossíntese , Óxido Nítrico/metabolismo , 4-Butirolactona/administração & dosagem , Endorribonucleases/administração & dosagem , Ativação Enzimática/efeitos dos fármacos , Hexilresorcinol/administração & dosagem , Óxido Nítrico Sintase/metabolismo , Estresse Fisiológico , Temperatura
4.
J Drug Target ; 10(3): 175-83, 2002 May.
Artigo em Inglês | MEDLINE | ID: mdl-12075818

RESUMO

Recently hydrophilic poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) was used for BS-RNase modification to prevent its degradation in bloodstream or fast elimination. Polymer-conjugated BS-RNase preparations proved to be cytotoxic after intravenous or intraperitoneal application, whereas native BS-RNase was ineffective. Here RNase A unimer was conjugated with two HPMA polymers (classic and star) and their antitumor effects both in vitro and in vivo were compared with those of BS-RNase polymers. Surprisingly, the antitumor effect of RNase A conjugates was also pronounced. The RNase A conjugates (classic and star) injected intravenously to mice bearing melanoma tumor caused a significant reduction in tumor volume following ten doses of 5 and 1 mg/kg, respectively. Despite the antitumor activity observed in vivo, the in vitro tested cytotoxic activity of RNase A did not differ from that caused by native RNase A while native BS-RNase (50 microg/ml) totally inhibited DNA synthesis in treated cells. The experiments with 125I-labeled preparations demonstrated concentration-dependent internalization of native BS-RNase by tumor cells within an hour, whereas the polymer conjugate (S-BS) was not internalized. On the contrary, the in vivo experiments showed that whereas 40% of S-BS conjugate persisted in bloodstream for 24h after administration, 98% of the native BS-RNase was already eliminated. Improved antitumor activities of PHPMA-modified RNases in vivo might be ascribed to their prolonged retention in bloodstream, better proteolytic stability and resistance to the action of the ribonuclease inhibitor.


Assuntos
Antineoplásicos/uso terapêutico , Endorribonucleases/uso terapêutico , Melanoma Experimental/tratamento farmacológico , Ácidos Polimetacrílicos/administração & dosagem , Ribonuclease Pancreático/uso terapêutico , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/química , Sítios de Ligação/fisiologia , Bovinos , Relação Dose-Resposta a Droga , Vias de Administração de Medicamentos , Portadores de Fármacos , Endorribonucleases/administração & dosagem , Endorribonucleases/química , Feminino , Humanos , Injeções Intraperitoneais , Injeções Intravenosas , Radioisótopos do Iodo , Linfócitos/metabolismo , Melanoma Experimental/patologia , Camundongos , Camundongos Nus , Estrutura Molecular , Ácidos Polimetacrílicos/química , Conformação Proteica , Ribonuclease Pancreático/administração & dosagem , Ribonuclease Pancreático/química , Células Tumorais Cultivadas/metabolismo , Ensaios Antitumorais Modelo de Xenoenxerto
5.
Neoplasma ; 48(2): 127-32, 2001.
Artigo em Inglês | MEDLINE | ID: mdl-11478693

RESUMO

Bovine seminal ribonuclease (BS-RNase) exerts a potent cytotoxic activity when administered intratumorally (i.t.) to the nude mice bearing human tumors. The ineffective treatment with intravenous (i.v.) or intraperitoneal (i.p.) administration led us to the synthesis of polymeric conjugates with BS-RNase to prevent it from degradation in the blood vessel. Hydrophilic poly[N-(2-hydroxypropyl)methacrylamide] (PHPMA) was used for BS-RNase modification and a PHPMA-BS-RNase conjugates were prepared. Classic conjugate (P-BS) with BS-RNase bound to the polymer by its oligopeptide site chains was prepared by aminolytic reaction of the polymer precursor bearing reactive ester groups situated in the side chains of polymer, while star-like conjugate (S-BS) was synthesized by the reaction of PHPMA containing end-chain reactive group with BS-RNase in aqueous buffer solution at pH 8. In contrast to the total ineffectiveness of free BS-RNase administered i.v. at a daily dose 10 mg/kg, application of P-BS and S-BS conjugates at doses 2 mg/kg and 0.5 mg/kg caused significant inhibition of the growth of human melanoma in nude mice. On the base of these results the effect of i.v. administered S-BS on the metastatic process and the survival of C57Bl/6 inbred mice inoculated with B16 melanoma cells was investigated. Sixty per cent of mice treated with S-BS (0.5 mg/kg/day) survived 100 days without metastatic foci when the experiment terminated. The average survival time of the treated groups was 75.5 days compared to 32.7 days in the control group. BS-RNase conjugated to water soluble polymers appears to be the first BS RNase preparation which exerts anticancer and antimetastatic activity following its intravenous administration.


Assuntos
Antineoplásicos/uso terapêutico , Endorribonucleases/uso terapêutico , Melanoma Experimental/tratamento farmacológico , Melanoma/tratamento farmacológico , Melanoma/secundário , Metástase Neoplásica/prevenção & controle , Animais , Antineoplásicos/administração & dosagem , Antineoplásicos/toxicidade , Bovinos , Relação Dose-Resposta a Droga , Portadores de Fármacos , Endorribonucleases/administração & dosagem , Endorribonucleases/toxicidade , Feminino , Humanos , Injeções Intraperitoneais , Injeções Intravenosas , Melanoma/patologia , Melanoma Experimental/patologia , Melanoma Experimental/secundário , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Nus , Ácidos Polimetacrílicos
6.
Regul Toxicol Pharmacol ; 33(1): 2-11, 2001 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11259174

RESUMO

The toxicity of Enzyme RP-1, an enzyme preparation used to hydrolyze yeast RNA to produce flavor enhancers for use in the food industry, was evaluated in a series of studies. A 5-week dietary toxicity study in Wistar rats was conducted in which animals received Enzyme RP-1 in feed at concentrations of 0, 500, 2000, or 8000 mg/kg body wt/day. A 13-week dietary toxicity study in Sprague-Dawley rats was conducted in which animals received RP-1 concentrate at 0, 0.125, 0.5, or 2% in their diets. At the highest dose levels in both studies, submandibular glands in the oral cavity were enlarged, an effect attributed to protease activity of the enzyme preparation. The no-observed-effect level in rats in the 13-week study was 0.5%, equivalent to 317 mg/kg body wt/day for males and 346 mg/kg body wt/day for females. Based on estimated dietary exposure to the enzyme preparation, the margin of exposure is estimated to be greater than 38,000. Lack of genotoxic potential was demonstrated by an in vitro reverse mutation assay in Salmonella typhimurium strains TA98, TA100, TA1535, and TA1537 and in Escherichia coli strain WP2uvr and by an in vitro chromosome aberration test in CHL/IU cells derived from fibroblasts from the lungs of Chinese hamsters. Finally, the particular strain of Penicillium citrinum, the fungal strain used to prepare Enzyme RP-1, was shown to have low pathogenicity upon a single injection into the tail vein of rats of viable spores at doses up to 2.8x10(5) colony-forming units per animal. The results of these studies demonstrate that the enzyme preparation may be considered safe to workers and consumers when employed in the production of flavor enhancers from yeast.


Assuntos
Endorribonucleases/efeitos adversos , Proteínas de Escherichia coli , Aromatizantes/efeitos adversos , Penicillium/enzimologia , RNA Catalítico/efeitos adversos , Administração Oral , Animais , Relação Dose-Resposta a Droga , Endorribonucleases/administração & dosagem , Endorribonucleases/metabolismo , Feminino , Aromatizantes/administração & dosagem , Aromatizantes/metabolismo , Indústria Alimentícia , Masculino , RNA Catalítico/administração & dosagem , RNA Catalítico/metabolismo , Ratos , Ratos Sprague-Dawley , Ratos Wistar , Ribonuclease P
7.
Oncol Rep ; 7(2): 363-7, 2000.
Artigo em Inglês | MEDLINE | ID: mdl-10671687

RESUMO

Bovine seminal ribonuclease (BS-RNase) is a homologue of RNase A with specific antitumor activities. It is selectively toxic for neuroblastoma (NB) cells in vitro with no significant effects on the viability of normal human cells. We evaluated the antitumoral effects of BS-RNase on human NB xenografts from UKF-NB-3 cells in athymic (nude) mice. The efficacy of direct intraneoplastic, subcutaneous and systemic delivery of BS-RNase was explored. Systemic administration of BS-RNase (12.5 mg/kg/day intraperitoneally, for 20 days in the course of four weeks) suppressed tumor growth but was not able to induce any cures. Subcutaneous injections (12.5 mg/kg/day for 20 days in the course of four weeks) and intratumoral BS-RNase treatment using the same schedule resulted in complete tumor regression. During 30 days following cessation of treatment no tumor regrowth was observed and animals were free of tumors. Toxic effects of BS-RNase (e.g., on bone marrow and inner organs) were not apparent. This data indicates that BS-RNase fulfills important criteria for a candidate antitumor agent specific for NB.


Assuntos
Antineoplásicos/administração & dosagem , Neoplasias Encefálicas/tratamento farmacológico , Neoplasias Encefálicas/patologia , Endorribonucleases/administração & dosagem , Neuroblastoma/tratamento farmacológico , Neuroblastoma/patologia , Animais , Antineoplásicos/uso terapêutico , Bovinos , Divisão Celular/efeitos dos fármacos , Endorribonucleases/uso terapêutico , Humanos , Masculino , Camundongos , Camundongos Nus , Transplante de Neoplasias
8.
Folia Microbiol (Praha) ; 43(5): 511-2, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9821313

RESUMO

Unlike the bovine pancreatic ribonuclease (RNAase A), bovine seminal ribonuclease (BS RNAase) displays various biological activities including antitumor cytotoxicity. To learn more about its antitumor activity, we investigated BS RNAase effect on athymic nude mice bearing various tumors. BS RNAase (250 micrograms per mouse per day) was administered to the mice with prostate carcinoma for three weeks by three different routes (intraperitoneally--i.p., subcutaneously--s.c., and intratumorally-i.t.). Administration i.p. was ineffective, while s.c. administration reduced significantly size of tumors and i.t. administration abolished half of the tumors in treated mice. The i.t. administration of BS RNase to nude mice bearing melanoma showed even better results. Eighty % of mice were without tumors and in the other mice the tumors were significantly diminished. The best antitumor effect was obtained in case of seminoma. All mice bearing this tumor were cured after ten doses of BS RNAase.


Assuntos
Antineoplásicos/uso terapêutico , Endorribonucleases/uso terapêutico , Neoplasias Experimentais/tratamento farmacológico , Animais , Antineoplásicos/administração & dosagem , Bovinos , Ensaios de Seleção de Medicamentos Antitumorais , Endorribonucleases/administração & dosagem , Feminino , Masculino , Melanoma/tratamento farmacológico , Camundongos , Camundongos Nus , Transplante de Neoplasias , Neoplasias da Próstata/tratamento farmacológico , Seminoma/tratamento farmacológico , Transplante Heterólogo
9.
Toxicology ; 120(1): 55-63, 1997 Jun 06.
Artigo em Inglês | MEDLINE | ID: mdl-9160109

RESUMO

Alterations of the renal function in the isolated perfused rat kidney system after application of two bacterial RNases, Bacillus intermedius RNase (binase) and ribonuclease produced by Bacillus amyloliquefaciens (barnase), were investigated with two different treatment regimens in comparison with catalytically inactive derivates of the enzymes, photooxidated at the active site His101 binase and inactive mutant His102Gln barnase. For the in vitro approach the test enzymes were dissolved in the perfusion media and applied to the kidney after removal from the animal. Alternatively, the test ribonucleases were administered to rats in vivo and the renal effects were assessed in the isolated perfused rat kidney 1 and 6 h after treatment. In the in vitro regimen both active enzymes induced time- and concentration-dependent nephrotoxicity reflected in enhancement of urinary protein excretion, decline of glucose reabsorption, increase of gamma-glutamyltranspeptidase and alkaline phosphatase activities in urine. In vivo administration of active binase induced functional impairment of the isolated perfused organ in a similar way. None of the inactive RNases in both regimens and at all concentrations tested altered any renal parameter. The results suggest that RNA degradation may be involved in the nephrotoxic effects of bacillar RNases.


Assuntos
Endorribonucleases/farmacologia , Rim/efeitos dos fármacos , Ribonucleases/farmacologia , Fosfatase Alcalina/urina , Animais , Proteínas de Bactérias , Endorribonucleases/administração & dosagem , Glicosúria/etiologia , Glicosúria/urina , Técnicas In Vitro , Injeções Intraperitoneais , Rim/metabolismo , Rim/fisiopatologia , Masculino , Perfusão , Proteinúria/etiologia , Proteinúria/urina , Ratos , Ratos Wistar , Ribonucleases/administração & dosagem , gama-Glutamil Hidrolase/urina
10.
Cancer Res ; 54(16): 4253-6, 1994 Aug 15.
Artigo em Inglês | MEDLINE | ID: mdl-8044766

RESUMO

The role of some RNases as antitumoral agents has been recently emphasized. We have previously demonstrated a striking inhibitory effect of bovine seminal RNase on the in vitro growth of tumor cells of metastatic origin. This has prompted us to test the effects of this protein in vivo on the induction of metastatic foci in mice lungs after i.m. injection of a highly metastatic Lewis lung carcinoma cell line. The results presented here, while confirming and expanding upon those previously reported on the antitumor effects of bovine seminal RNase in vivo on primary thyroid epithelial tumors, indicate for the first time that bovine seminal RNase can also be regarded as a potent antimetastatic agent on in vivo spontaneous metastases.


Assuntos
Endorribonucleases/uso terapêutico , Glândulas Seminais/enzimologia , Animais , Carcinoma/patologia , Carcinoma/secundário , Carcinoma/terapia , Bovinos , Ensaios de Seleção de Medicamentos Antitumorais , Endorribonucleases/administração & dosagem , Neoplasias Pulmonares/patologia , Neoplasias Pulmonares/secundário , Neoplasias Pulmonares/terapia , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Tamanho do Órgão , Ratos , Ratos Endogâmicos Lew , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/terapia , Células Tumorais Cultivadas
11.
Khirurgiia (Mosk) ; (9): 69-73, 1990 Sep.
Artigo em Russo | MEDLINE | ID: mdl-2273853

RESUMO

The authors discuss the results of application of proteinase preparations immobilized on a water soluble carrier (Immozymase) and a water insoluble carrier (Profezyme) in the management of ++pyo-necrotic processes of various etiology and localization in 1,059 patients. The wounds were cleansed 1.5-2 times quicker than with the traditional methods of treatment. Immobilized proteinases possessing a prolonged therapeutic effect were found to stimulate the regeneration process. The authors believe the use of Immozymase to be promising in the treatment of purulent foci which are drained with difficulty and in intracavitary administration for treating purulent processes in the thoracic or abdominal cavity.


Assuntos
Bactérias/enzimologia , Infecções Bacterianas/tratamento farmacológico , Endopeptidases/administração & dosagem , Endorribonucleases/administração & dosagem , Enzimas Imobilizadas/administração & dosagem , Peptídeo Hidrolases/administração & dosagem , Polietilenoglicóis/administração & dosagem , Dermatopatias Infecciosas/tratamento farmacológico , Infecção dos Ferimentos/tratamento farmacológico , Portadores de Fármacos , Humanos , Solubilidade , Água
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA